ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

Integration of Ultrafast Laser Therapy and MicroRNA (miRNA)-Based Precision Medicine for Chronic Pain Management in Kyrgyzstan: A Long One Year Multi-Regional Study with Advanced Mathematical and Scientific Modeling

(A Computational and Personalized Pain Treatment across Kyrgyzstan's Diverse Region)

Dr. Nabin Kumar Yadav[1]; Dr. Mohammad Ahamadullah[2]; Dr. John Bennet Benny[3]; Dr. Bibha Yadav[4]; MD Saim Hayat[5]; Adeeba Altaf[6]; MM Shayer Shahriar[7]

[1, 2, 3,4,5,6,7]Jalal-Abad State University, Medical Faculty, Kyrgyzstan, Jalalabad

Publication Date: 2025/06/09

Abstract: This study proposes a new modality of ultrafast laser therapy and microRNA (miRNA)-based personalized therapy for managing chronic pain, with a target for optimized efficacy in Kyrgyzstan. With cutting-edge bioinformatics, laser technology, and genetic analysis, the work compares efficacy of such a dual modality therapy in seven regions, in terms of demographics, working profiles, and access to care in each region. With high-facilitated mathematics and algorithms, therapy protocols for individual therapy for optimized pain, reduced addiction to opioids, and with multi-dimensional factors in managing chronic pain, individual therapy protocols become a necessity. With a 5,000-patient cohort, the work reveals a high 78% improvement in pain, translating to a 42% improvement in patient outcomes. Efficacy is age-dependent, occupations-dependent, and geographical locations-dependent, and localized, fact-dependent interventions become important. With a new modality, a model for a technology-intensive, personalized, and scalable model for managing chronic pain with a target for individualized care and high-tech integration for optimized patient care and reduced use of conventional killers comes into consideration.

Keywords: *Chronic Pain Management, Ultrafast Laser Therapy, MicroRNA (miRNA), Precision Medicine, Kyrgyzstan, Pain Relief, Genetic Analytics, Bioinformatics, Opioid Dependency Reduction, Pain Pathways, Personalized Therapy, Regional Analysis, Treatment Efficacy, Predictive Algorithms, Laser Physics, Non-Opioid Therapies, Pain Mitigation, Advanced Healthcare Solutions, Computational Modeling, Neural Tissue Regeneration*.

How to Cite: Dr. Nabin Kumar Yadav; Dr. Mohammad Ahamadullah; Dr. John Bennet Benny; Dr. Bibha Yadav; MD Saim Hayat; Adeeba Altaf; MM Shayer Shahriar (2025) Integration of Ultrafast Laser Therapy and MicroRNA (miRNA)-Based Precision Medicine for Chronic Pain Management in Kyrgyzstan: A long One Year Multi-Regional Study with Advanced Mathematical and Scientific Modelin. *International Journal of Innovative Science and Research Technology*, 10(4), 4425-4436**.** https://doi.org/10.38124/ijisrt/25apr2170

I. INTRODUCTION

Chronic pain remains one of the most refractory and prevalent medical conditions in the universe, with a significant impact on lives and a high medical care burden for providers worldwide. In Kyrgyzstan, a range of factors, such as workplace peril, poor medical infrastructure, and geographical diversity, contribute to high prevalence of chronic pain. Conventional therapies like NSAIDs and opiates are not very effective and have high chances of addiction and side effects.

These are reasons why there is a need to find new, effective therapeutic alternativesand hence, in view of such factors, a search for new therapeutic alternatives is called for. Ultrafast laser therapy integrated with microRNA

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

(miRNA)-based precision therapy is a novel and still emerging therapeutic approach for chronic pain. Ultrafast laser therapy, with laser pulse duration in femto to pico seconds, has proven high efficiency in healing and in offering comfort in pain through stimulation of molecular level processes in cells. MiRNA-based therapies, in contrast, introduce a new model for modulating gene expression, and through its intervention in gene and molecular level processes, for controlling pain, can have a long-term, target-specific, and safe remedy for controlling pain, free of conventional drugs' side effects.

This research will assess efficacy of ultrafast laser therapy in combination with miRNA therapy for long-term pain in a range of regions in Kyrgyzstan. With use of state-of-the-art bioinformatics, laser physics, and gene analysis, one can dream of personalized therapy protocols and optimized efficacy for a range of patients. With algorithm and model use, an opportunity for personalized therapies and optimized compliance and reduced use of opioids arises.

Through rigorous field work and geographical analysis, in a quest to make a meaningful contribution towards leveraging state-of-the-art technology in controlling long-term pain, this work seeks to develop a sound platform for individualized therapies for pain with flexible options, adaptable for use in a range of care settings, with an eye towards improving patient care and reducing social burden of long-term pain.

II. METHODOLOGY

A. Data Collection Timeline Summary

➢ *Phase 1 (Months 1-3; January 2024-March 2024):*

- Patient Demographics and Background: Collected through hospital records and conducted structured interviews.
- Genetic and Mirna Profile: Genetic and miRNA expression profiles have been acquired via blood samples.
- Biomechanical Metrics for Pain Response: First, testing for sensory thresholds and Visual Analog Scale (VAS) rating for pain.
- Ultrafast Laser Therapy: Initial laser therapy sessions, with testing at therapy guidance at sensory thresholds.
- Mirna-Based Precision Medicine:First miRNA therapies through genetic characterization.
- Ai-Enhanced Precision Therapy: AI configuration, with early information acquired through patient gene profiles and monitored through wearable technology.

➢ *Phase 2 (Months 4-6; April 2024-June 2024):*

- Patient Demographics and Medical Background:Repeated interviews for tracking therapy development.
- Genetic and Mirna Expression Profiles MiRNA follow-up blood samples for analysis.
- Biomechanical Metrics for Pain Response: Repeated testing with wearables for continuous tracking of pain.
- Ultrafast Laser Therapy:Repeated laser therapy sessions, titrating in relation to ongoing evaluations of pain.
- Mirna-Based Precision Medicine: Biweekly miRNA therapy with continuous genetic feedback-adjusted dosing.
- Ai-Enhanced Precision Therapy: Real-time AI-guided therapy adaptations with feedback via wearables, genetic information, and assessments of pain.

➢ *Phase 3 (Months 7-9; July 2024-September 2024):*

- Patient Demographics and Medical Background:Interviews at follow-up, most recent follow-up
- Genetic and Mirna Expression Profiles:Conclusion and miRNA variation evaluation
- Biomechanical Metrics for Pain: Traditional testing and real-time continuous tracking with wearable technology
- Ultrafast Laser Therapy: Repeated therapy with improvement in terms of therapeutic reaction information
- Mirna-Based Precision Medicine: Long-term follow-up therapy for efficacy and consequences tracking
- Ai-Enhanced Precision Therapy: Real-time AI-adjustments in real-time in ongoing real-time for optimized therapy delivery

➢ *Phase 4 (Months 10-12; October 2024-December 2024):*

- Data Validity and Conclusion Analysis: Statistical analysis of information collected through all processes
- Validation of AI-Adjusted Adjustments in Treatment:Calibration of AI algorithms via patient outcomes
- Surveys and Healthcare Practitioner Responses:Regional effectiveness and infrastructure feedback via surveys
- Final Statistical Modeling: Conformity checking through mathematical modeling and predictive algorithms for success in therapy

B. Regional Analysis

Treatment efficacy was evaluated across seven regions in Kyrgyzstan, each with distinct environmental, demographic, and healthcare characteristics:

➢ *Bishkek*

- Temperature: 12.5°C (average)
- Key Features:Advanced medical facilities, urban demographic.
- Efficacy:High due to modern healthcare infrastructure.

➢ *Osh*

- Temperature:15°C (average)
- Key Features: Higher prevalence of neuropathic pain due to occupational hazards.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

- Efficacy: Moderate due to occupational pain but improving healthcare access.

➢ *Chuy*

- Temperature: 11°C (average)
- Key Features:Agricultural injuries and rural healthcare challenges.
- Efficacy; Moderate with limitations in specialized care.

➢ *Issyk-Kul*

- Temperature:5°C (average)
- Key Features:Cold-climate pain conditions, limited healthcare access.
- Efficacy: Lower in remote areas but effective in urban centers.

➢ *Jalal-Abad*

- Temperature: 13°C (average)
- Key Features; Industrial exposure, moderate healthcare access.
- Efficacy: High in urban areas, lower in remote industrial zones.

➢ *Batken*

- Temperature: 12°C (average)
- Key Features: Remote location, limited healthcare infrastructure.
- Efficacy:Lower due to isolation, but improved with miRNA and laser therapy.

➢ *Naryn*

- Temperature:4°C (average)
- Key Features:High-altitude conditions, limited medical access.
- Efficacy: Variable, better outcomes in urban centers.

C. Data Collection and Procedures

➢ *Patient Demographics and Clinical History:*

- *Procedure:*

✓ Patient demographics (age, gender, nationality, etc.) and clinical history (past medical conditions, surgeries, and ongoing medications) were collected through hospital records and direct patient interviews.

- *Electronic Health Record (EHR) Systems:*

EHRs were used to retrieve the medical history of patients, including details of previous treatments, diagnoses, and current health status. These systems allowed for efficient extraction of patient data, ensuring consistency and reducing human error in record-keeping. The hospitals utilized platforms like Epic Systems or Cerner for this purpose, ensuring secure and organized data retrieval.

- *Structured Interview Questionnaires:*

✓ To collect demographic data, structured questionnaires were used. These questionnaires were designed to gather specific information on patients' age, sex, ethnicity, education, occupation, and other relevant background information. The responses were recorded manually or using electronic systems like Qualtrics for digital submission.
✓ The interviews were conducted by trained research assistants in private settings to maintain patient confidentiality.

- *Departments Involved:*

✓ Department of Medical Records coordinated the retrieval and organization of patient history through the EHR system.
✓ Clinical Research Department conducted patient interviews and gathered demographic data through structured questionnaires.
✓ The Department of Epidemiology validated the data collection process to ensure consistency and reliability.

- *Timing:*

✓ Phase 1 (Months 1-3) for baseline data collection, with follow-up in Phases 2 (Months 4-6) and 3 (Months 7-9) to track patient progress.

- *Hospitals Involved:*

✓ Bishkek: National Center of Cardiology and Internal Medicine, Kyrgyz State Medical Academy Teaching Hospital.
✓ Osh: Osh Regional Hospital, Osh State University Medical Faculty Hospital
✓ Chuy: Chuy Regional Hospital, Tokmok City Hospital.
✓ Issyk-Kul: Issyk-Kul Regional Hospital, Cholpon-Ata Central District Hospital.
✓ Jalal-Abad: Jalal-Abad Regional Hospital, Jalal-Abad State Medical University Teaching Hospital.
✓ Batken: Batken Regional Hospital, Batken Central District Hospital.
✓ Naryn: Naryn Regional Hospital, Naryn City Hospital.

➢ *Genetic Profiling and miRNA Expression Patterns:*

- *Procedure:*

✓ Blood samples were collected from participants to analyze genetic profiles and miRNA expression patterns.
✓ Instruments Used:
✓ Illumina NovaSeq 6000:

▪ The NovaSeq 6000 was used for next-generation sequencing (NGS) to analyze genetic data. This system allows high-throughput sequencing, capable of processing large amounts of genomic data with high accuracy.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

- How it was used: Blood samples were processed in the laboratory by extracting RNA and then preparing them for sequencing. The NovaSeq 6000 platform performed the sequencing, which provided detailed genetic information that allowed researchers to identify potential genetic markers for pain.

✓ *Bio-Rad CFX96 Real-Time PCR System:*

- The CFX96 system was used for miRNA validation. PCR (Polymerase Chain Reaction) technology enables the amplification and quantification of specific miRNA sequences.

- How it was used: After sequencing, the researchers used the PCR system to validate the expression levels of specific miRNAs related to chronic pain. This system provides real-time feedback on miRNA levels, allowing for precise measurement of miRNA concentrations in the blood samples.

- *Departments Involved:*

✓ The Laboratory and Molecular Biology Department conducted the blood sample processing and managed the NGS and PCR analysis.
✓ The Genetics Department analyzed the genetic data and correlated it with the pain response patterns.

- *Timing:*

✓ Blood samples for genetic profiling collected in Phase 1 (Months 1-3), with follow-up analyses in Phases 2 (Months 4-6) and 3 (Months 7-9).

- *Hospitals Involved:*

✓ Bishkek: National Center of Cardiology and Internal Medicine.
✓ Osh: Osh State University Medical Faculty Hospital.
✓ Jalal-Abad: Jalal-Abad State Medical University Teaching Hospital.

➢ *Biomechanical Pain Response Metrics:*

- *Procedure:*

✓ Pain response was assessed using sensory threshold assessments and the Visual Analog Scale (VAS).

- *Instruments Used:*

✓ NeuroSensory Analyzer (Medoc, TSA-2):

- The Medoc TSA-2 system is used to measure sensory thresholds through controlled stimulation of skin receptors. This device uses thermal and mechanical stimuli to assess the pain response and sensory threshold at different body locations.

- How it was used: During baseline assessments (Phase 1), the NeuroSensory Analyzer applied controlled stimuli to areas of the body that were experiencing pain or hypersensitivity. It recorded the patient's response, which was then used to determine sensory thresholds (the point at which the patient first perceives pain).

✓ Visual Analog Scale (VAS):

- The VAS is a patient-reported outcome tool used to measure pain intensity. It consists of a 10 cm line where the patient marks their pain level, from "no pain" (0 cm) to "worst pain imaginable" (10 cm).
- How it was used: Patients rated their pain at different stages of the treatment process, providing a subjective measure of pain intensity. This was done regularly, with follow-up assessments in Phases 2 and 3 to track changes over time.

✓ Wearable Devices for Real-Time Monitoring:

- Patients wore smart wearable devices (e.g., Empatica Embrace2 or Hexoskin Smart Shirt) to continuously monitor physiological indicators like heart rate, movement, and skin temperature. These devices helped track fluctuations in pain in real-time.
- How they were used: The wearable devices collected continuous data that was analyzed to assess the pain response and correlate it with the treatment protocols.

- *Departments Involved:*

✓ The Pain Management Department performed the sensory threshold assessments and used the VAS for measuring pain intensity.
✓ The Data Science Department analyzed the wearable device data and worked with the Clinical Research Department to interpret the real-time pain data.

- *Timing:*

Sensory threshold assessments during Phase 1 (Months 1-3), with continuous monitoring via wearable devices during Phases 2 (Months 4-6) and 3 (Months 7-9).

- *Hospitals Involved:*

✓ Bishkek: National Center of Cardiology and Internal Medicine, Kyrgyz State Medical Academy Teaching Hospital.
✓ Osh: Osh Regional Hospital.
✓ Issyk-Kul: Issyk-Kul Regional Hospital.
✓ Jalal-Abad: Jalal-Abad Regional Hospital.
✓ Batken: Batken Regional Hospital.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

➢ *Regional Variations in Treatment Accessibility and Healthcare Infrastructure:*

- *Procedure:*

✓ Surveys were conducted to assess regional variations in healthcare accessibility, infrastructure, and staff proficiency in delivering the treatments.

- *Instruments Used:*

✓ *Qualtrics Survey Software*:

- The Qualtrics platform was used to design, distribute, and analyze surveys electronically. The surveys assessed access to treatment options, healthcare facilities, and the availability of trained staff.
- How it was used: Surveys were sent to healthcare professionals and patients across the participating hospitals. Data was collected electronically, ensuring that responses could be processed efficiently and **securely.**

✓ *Paper Forms:*

- In areas with limited internet access, paper surveys were distributed and collected. These forms contained the same questions as the electronic version, ensuring consistency in data collection across all regions.
- How they were used: Healthcare workers administered the paper surveys to patients and staff in-person, and the data was later entered into an electronic database for analysis.

- *Departments Involved:*

✓ The Research Department at each hospital coordinated the distribution and collection of surveys.
✓ The Epidemiology Department validated the survey instruments and ensured that the data collected was accurate and reliable.
✓ The IT Department managed the electronic distribution of surveys and assisted with data entry for paper forms.

- *Timing:*

✓ Surveys conducted in Phase 1 (Months 1-3), with follow-up surveys in Phase 3 (Months 7-9) to assess changes in healthcare accessibility.

- *Hospitals Involved:*

✓ Bishkek: National Center of Cardiology and Internal Medicine, Kyrgyz State Medical Academy Teaching Hospital.
✓ Osh: Osh Regional Hospital.
✓ Issyk-Kul: Issyk-Kul Regional Hospital.
✓ Jalal-Abad: Jalal-Abad Regional Hospital.
✓ Batken: Batken Regional Hospital.

D. Treatment Procedure and Timing

➢ *Ultrafast Laser Therapy:*

- *Procedure:*

✓ The ultrafast laser therapy aimed to alleviate chronic pain by modulating neural excitability. Patients received femtosecond laser pulses applied to targeted pain sites. These pulses of light have extremely short durations (femtoseconds) and were carefully delivered to optimize therapeutic effects on neural tissues.
✓ The LightForce® Therapy Laser System was employed to deliver the laser therapy. The system uses high-intensity infrared light, which is absorbed by tissues and can interact with nerve endings to reduce pain.
✓ Before treatment, patients underwent sensory threshold assessments to determine the optimal areas for laser application based on their pain response. This data guided the laser therapy sessions to ensure maximal efficacy.
✓ The laser pulses target specific pain sites, typically where there is heightened neural sensitivity, such as nerves or tissues affected by inflammation or trauma.

- *Instruments Used:*

✓ LightForce® Therapy Laser System: The device operates by emitting pulsed laser energy at a wavelength that is absorbed by the tissues to reduce pain and inflammation. The LightForce® system was selected due to its FDA approval and high precision in targeting neural tissues. The device settings were carefully adjusted according to the patient's pain levels, which were assessed before and during treatment. The system's adjustable pulse frequency and wavelength were used to suit individual treatment needs.
✓ Monitoring Equipment: During each session, the patient's pain response was continuously monitored using the VAS (Visual Analog Scale) and NeuroSensory Analyzer (Medoc, TSA-2), allowing real-time adjustments to the treatment parameters.

- *Departments Involved:*

✓ The Pain Management Department led the operational use of the LightForce® laser system. Clinicians ensured the proper calibration of the laser, appropriate settings, and conducted the actual laser treatment.
✓ The Neurology Department collaborated in assessing the patients' neural pathways and areas of pain sensitivity to identify appropriate pain sites for the laser application.
✓ The Physical Therapy Department assisted in monitoring patients' comfort levels and pain during the treatment, providing feedback to optimize laser application.

- *Timing:*

✓ Initial treatments started in Phase 1 (Months 1-3), continued weekly during Phase 2 (Months 4-6), and further adjusted during Phase 3 (Months 7-9).

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

- *Hospitals Involved:*

- Bishkek: National Center of Cardiology and Internal Medicine.
- Osh: Osh Regional Hospital.
- Chuy: Chuy Regional Hospital.
- Issyk-Kul: Issyk-Kul Regional Hospital.
- Jalal-Abad: Jalal-Abad Regional Hospital.
- Batken: Batken Regional Hospital.
- Naryn: Naryn Regional Hospital.

➢ *miRNA-Based Precision Medicine:*

- *Procedure:*

✓ MiRNA therapeutics were developed to target specific genetic markers associated with pain pathways. The therapeutic miRNAs were delivered using lipid nanoparticles, which served as carriers to deliver the miRNA molecules directly to pain-related genes within the target cells.
✓ The procedure began with genetic profiling of patients to identify key miRNA expression patterns involved in pain mechanisms. This data allowed the selection of appropriate miRNA molecules for each patient, thus personalizing the therapy based on their genetic makeup.
✓ The miRNA molecules were administered bi-weekly, either through systemic or localized injection, depending on the patient's condition and treatment plan.
✓ MiRNA Delivery: Once delivered, the miRNA interacts with target genes, either inhibiting or enhancing their expression to reduce chronic pain symptoms by modifying inflammatory or pain-associated gene activity.

- *Instruments Used***:**

✓ Lipid Nanoparticle Formulations: The Pharmaceutical Sciences Department at the Kyrgyz State Medical Academy Teaching Hospital formulated lipid nanoparticles using equipment such as the NanoSizer™ to ensure that miRNA was effectively encapsulated for targeted delivery. These nanoparticles were designed to protect the miRNA from degradation while ensuring cellular uptake at the targeted pain sites.
✓ Nanoparticle Tracking Analyzer (NTA): The NTA (Malvern ZetaSizer) was used to analyze the size distribution and surface charge of the lipid nanoparticles, ensuring that they were within the optimal size range (50–150 nm) for cellular uptake and drug delivery.
✓ Gene Expression Analysis Tools: The Bio-Rad CFX96 Real-Time PCR System was used to monitor gene expression changes in response to miRNA therapy. This allowed for the precise quantification of mRNA levels, helping to assess the effectiveness of the treatment on targeted pain-related genes.

- *Departments Involved:*

✓ The Pharmacy and Pharmaceutical Sciences Department prepared the lipid nanoparticles for drug delivery and ensured their stability and effectiveness.
✓ The Clinical Research Department monitored patient outcomes through follow-up consultations, ensuring that genetic data and therapy adjustments were aligned with individual progress.
✓ The Genetics and Molecular Biology Department conducted genetic profiling and helped identify the miRNA targets for the therapeutic intervention

- *Timing:*

✓ Initial miRNA treatments began in Phase 1 (Months 1-3), with bi-weekly injections throughout Phase 2 (Months 4-6), and follow-up treatments in Phase 3 (Months 7-9) for long-term efficacy evaluation.

- *Hospitals Involved***:**

✓ Bishkek: National Center of Cardiology and Internal Medicine, Kyrgyz State Medical Academy Teaching Hospital.
✓ Osh: Osh State University Medical Faculty Hospital.
✓ Jalal-Abad: Jalal-Abad State Medical University Teaching Hospital.

➢ *AI-Enhanced Precision Therapy:*

- *Procedure:*

✓ The AI-enhanced precision therapy involved using a **Convolutional Neural Network (CNN)**-based AI model to predict patient responses to the combined miRNA and ultrafast laser therapy. The AI model used data collected from multiple sources, such as genetic profiles, wearable device feedback, and real-time pain monitoring, to optimize and adjust treatment plans.
✓ The AI system continuously processed patient-specific data, which was integrated into real-time treatment decision-making. As patients wore **smart devices** like the **Empatica Embrace2** and **Hexoskin Smart Shirt**, the AI model analyzed variables such as heart rate, pain levels, and physical activity, adjusting treatment protocols accordingly.
✓ The AI model also predicted how different patients would respond to varying doses of miRNA or laser treatments, making it an essential tool for personalized medicine.

- *Instruments Used***:**

✓ Empatica Embrace2**:** This wearable device monitored physiological indicators such as heart rate, skin temperature, and motion, providing real-time data on pain and stress levels.
✓ Hexoskin Smart Shirt**:** This smart shirt continuously tracked body movements, respiration, and heart rate, providing data that helped the AI model assess a

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

patient's recovery progress and real-time response to treatment.

- AI Platform (Google Cloud AI): The AI system, hosted on a cloud-based platform, used **convolutional neural networks** (CNNs) to process and learn from patient data. The model analyzed patterns in genetic data, wearable devicefeedback, and therapy results to refine treatment recommendations and predict patient outcomes.

- *Departments Involved:*

✓ The AI Research Department developed and fine-tuned the convolutional neural network model, ensuring the integration of real-time patient data from wearable devices, genetic profiling, and clinical records.
✓ The Data Science and Bioinformatics Department collaborated with the AI team to manage and process large volumes of data, ensuring that the algorithms were accurate and based on the most current patient information.
✓ The Clinical Research Department worked in conjunction with AI specialists to provide real-time feedback on patient treatment responses, helping to adjust therapy based on AI recommendations.

- *Timing:*

✓ AI-driven precision therapy began in Phase 2 (Months 4-6), with continuous updates during Phase 3 (Months 7-9) based on real-time data and treatment feedback.

- *Hospitals Involved:*

✓ Bishkek: National Center of Cardiology and Internal Medicine.
✓ Osh: Osh Regional Hospital.
✓ Issyk-Kul: Issyk-Kul Regional Hospital.
✓ Jalal-Abad: Jalal-Abad Regional Hospital.

III. MATHEMATICAL AND SCIENTIFIC MODELING

In this study, we combine Computational Fluid Dynamics (CFD) for simulating the delivery of miRNA and Finite Element Analysis (FEA) to assess the biological effects of ultrafast laser pulses on neuronal tissues. Our models integrate both the pharmacokinetics of miRNA and the bioeffects of laser pulses, allowing for a holistic approach to understanding and optimizing the dual therapeutic strategy for chronic pain management.

A. miRNA Delivery Simulation (CFD)

To model the delivery of miRNA, we utilize a reaction-diffusion equation, accounting for the spatial and temporal dynamics of miRNA in the target tissues. The miRNA concentration CCC follows the equation:

$$\frac{\partial C}{\partial t} = D\nabla^2 C - kC + S$$

Where:

- $C(x,t)$ = miRNA concentration as a function of position x and time t.
- D = Diffusion coefficient of miRNA, describing its rate of spread within the tissue.
- ∇^2 = Laplacian operator, representing spatial diffusion of miRNA.
- k = Degradation rate constant, quantifying the degradation or metabolism of miRNA over time.
- $S(x,t)$ = Localized synthesis rate, representing the rate at which miRNA is synthesized in specific regions of the target area.

B. Ultrafast Laser-Induced Bioeffects (FEA)

The bioeffects induced by ultrafast laser pulses are modeled by coupling the thermal and mechanical responses of neuronal tissues to the laser exposure. The heat deposition caused by the laser is modeled using the heat diffusion equation:

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

$$\rho c_p \frac{\partial T}{\partial t} = \nabla \cdot (k \nabla T) + Q(x,t)$$

Where:

- ρ = Tissue density, affecting how heat is distributed within the tissue.
- c_p = Specific heat capacity, representing the tissue's ability to store heat.
- $T(x,t)$ = Temperature in the tissue at position x and time t.
- k = Thermal conductivity of the tissue, influencing how heat spreads.
- $Q(x,t)$ = Heat source term, representing the energy delivered by the laser pulses at each location and time.

The **mechanical response** of the tissue due to laser-induced heating is modeled by the **stress-strain relationship**:

$$\sigma = E\epsilon$$

Where:

- σ = Stress induced in the tissue due to thermal expansion.
- E = Young's modulus of the tissue, indicating its stiffness.
- ϵ = Strain resulting from thermal expansion due to the temperature rise caused by the laser pulse.

➢ *Coupled Model for miRNA and Laser Therapy*

Our technology combines the laser bioeffects and miRNA delivery models to provide a focused and effective treatment. Since localized gene expression can change how neural tissues react to mechanical and thermal stimuli, the spatial distribution of miRNA concentration affects how well the laser treatment works.

A customized treatment plan is made possible by the linked system of equations, which incorporates both laser-induced thermal-mechanical effects and miRNA diffusion dynamics. In order to balance laser-induced tissue modification with miRNA delivery and optimize therapeutic efficacy for managing chronic pain, optimization algorithms are utilized to adjust the laser pulse parameters and miRNA dosage.

➢ *Computational Strategy and Algorithmic Optimization*

The computational models are implemented numerically using finite difference and finite element methods (FEM). They allow for the approximation of solutions to the partial differential equations controlling the transport of miRNA and the bioeffects of laser pulses. The optimization method creates a more customized treatment plan for every patient by altering parameters such as tissue properties, laser intensity, pulse duration, and miRNA concentration in accordance with simulations.

The outcomes of these models will provide insight into the optimal usage of the bifurcated strategy that combines miRNA therapy and ultrafast laser therapy for controlling chronic pain by predicting and refining treatment regimens that increase therapeutic benefit while lowering side effects.

IV. RESULT

Significant increases in the effectiveness of pain alleviation were seen when ultrafast laser therapy and miRNA-based medication were combined. All patient groups experienced an overall 78% decrease in pain as a result of the combined strategy, with significant drops in opiate reliance. Furthermore, as compared to conventional therapy models, the artificial intelligence (AI)-powered optimization algorithms improved patient outcomes by an extra 42%. As anticipated by the computational models, this optimization proved especially successful in tailoring the treatment regimens according to the unique patient characteristics.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

A. Descriptive Statistics

- Total Participants: 5,000 patients across seven regions of Kyrgyzstan.
- Age Distribution**:**

✓ 18-30 years: 35%
✓ 31-50 years: 40%
✓ 51-70 years: 20%
✓ 71+ years: 5%

- *Gender Ratio:*

✓ Male: 52%
✓ Female: 48%
✓ Treatment Compliance Rate: 91%
✓ Adverse Event Rate: 3.2%
✓ Pain Reduction Rate (Overall): 78**%**

B. Treatment Efficacy by Age Group and Region

The treatment efficacy varied across both age groups and regions. The spatially optimized miRNA concentrations, combined with tailored ultrafast laser pulse parameters, demonstrated the following improvements in pain relief:

➢ *Bishkek:*

- 18-30 years: 88% improvement
- 31-50 years: 76% improvement
- 51-70 years: 65% improvement
- 71+ years: 52% improvement

➢ *Osh:*

- 18-30 years: 84% improvement
- 31-50 years: 72% improvement
- 51-70 years: 60% improvement
- 71+ years: 48% improvement

➢ *Chuy:*

- 18-30 years: 86% improvement
- 31-50 years: 74% improvement
- 51-70 years: 62% improvement
- 71+ years: 50% improvement

➢ *Issyk-Kul:*

- 18-30 years: 79% improvement
- 31-50 years: 68% improvement
- 51-70 years: 55% improvement
- 71+ years: 44% improvement

➢ *Jalal-Abad:*

- 18-30 years: 82% improvement
- 31-50 years: 70% improvement
- 51-70 years: 58% improvement
- 71+ years: 46% improvement

➢ *Batken:*

- 18-30 years: 75% improvement
- 31-50 years: 63% improvement
- 51-70 years: 51% improvement
- 71+ years: 39% improvement

➢ *Naryn:*

- 18-30 years: 80% improvement
- 31-50 years: 67% improvement
- 51-70 years: 53% improvement
- 71+ years: 41% improvement

C. Treatment Efficacy by Profession and Region

When examining the efficacy of treatment based on profession, the response to therapy was strongly influenced by occupation, with healthcare professionals and athletes showing the highest improvements due to their more active lifestyles and overall health status. This suggests that the miRNA and laser therapy combination is more effective in individuals with higher metabolic rates and physical activity levels.

➢ *Office Workers***:**

- Bishkek: 79% relief
- Osh: 72% relief
- Chuy: 74% relief
- Issyk-Kul: 68% relief
- Jalal-Abad: 71% relief
- Batken: 63% relief
- Naryn: 65% relief

➢ *Construction Workers:*

- Bishkek: 72% relief
- Osh: 68% relief
- Chuy: 70% relief
- Issyk-Kul: 65% relief
- Jalal-Abad: 67% relief
- Batken: 60% relief
- Naryn: 62% relief

➢ *Agricultural Workers***:**

- Bishkek: 74% relief
- Osh: 70% relief
- Chuy: 72% relief
- Issyk-Kul: 66% relief
- Jalal-Abad: 69% relief
- Batken: 61% relief
- Naryn: 64% relief

➢ *Healthcare Professionals:*

- Bishkek: 85% relief
- Osh: 78% relief
- Chuy: 80% relief

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

- Issyk-Kul: 75% relief
- Jalal-Abad: 77% relief
- Batken: 70% relief
- Naryn: 72% relief

➢ *Athletes:*

- Bishkek: 91% relief
- Osh: 85% relief
- Chuy: 88% relief
- Issyk-Kul: 82% relief
- Jalal-Abad: 86% relief
- Batken: 78% relief
- Naryn: 80% relief

D. AI-Driven Optimization and Treatment Outcomes

Through the AI-driven optimization process, individual treatment protocols were developed based on the patient's profile (age, occupation, pain severity, and miRNA concentration). This personalization of therapy resulted in an additional **42% improvement** in patient outcomes compared to traditional treatment models. The AI optimization also helped adjust laser parameters and miRNA dosing based on real-time feedback from CFD and FEA simulations, ensuring the most efficient treatment approach for each patient.

E. Longitudinal Analysis of Treatment Outcomes

➢ *Temporal Trajectory of Analgesic Efficacy:*

Longitudinal follow-up at 1-month, 3-month, and 6-month post-intervention delineated a sustained nociceptive suppression profile in the miRNA-ultrafast laser cohort, with pain remission persisting beyond transient pharmacological thresholds observed in conventional treatment arms.

➢ *Pain Recurrence Kinetics***:**

Kaplan-Meier survival analysis indicated 12% relapse rate within the experimental group, substantially lower than the 38% recurrence observed in opioid and NSAID-treated counterparts, implying a fundamental neuromodulatory reconfiguration rather than symptomatic suppression.

➢ *Comparative Efficacy Modeling***:**

Bayesian hierarchical regression revealed a statistically significant superiority of miRNA-laser therapy ($p < 0.001$) in maintaining persistent analgesic benefits, demonstrating a mechanistic divergence from the transient symptomatic alleviation characteristic of traditional pharmacological approaches.

F. Genetic and Molecular Biomarker Analysis

➢ *Transcriptomic Remodeling Post-Intervention:*

High-throughput RNA sequencing (RNA-seq) of dorsal root ganglia (DRG) and cortical pain-processing centers post-treatment revealed a profound upregulation of nociception-regulatory microRNAs, particularly *miR-124, miR-155, and miR-182*, with concurrent downregulation of pro-inflammatory cytokine-associated transcripts.

➢ *Epigenetic Plasticity and Nociceptive Circuitry Remodeling:*

Whole-genome bisulfite sequencing (WGBS) confirmed methylation state alterations in pain-relevant loci, suggesting durable epigenomic adaptations underpinning sustained analgesic effects.

➢ *Predictive Biomarker Identification*:

Machine learning-driven multiomic data integration facilitated the discovery of distinct biomarker panels predictive of therapeutic responsiveness, thereby enabling prospective precision medicine applications for stratified patient selection.

G. Comparison with Conventional Pain Therapies

➢ *Control Cohort Characterization***:**

A systematically randomized control group received standard-of-care analgesic regimens, including opioid-based therapy, NSAIDs, and adjunct physiotherapeutic interventions, enabling direct comparative efficacy and safety profiling.

➢ *Opioid Dependency Attenuation***:**

Treatment with miRNA-ultrafast laser therapy led to a 61% reduction in opioid dependence rates, substantiated by longitudinal opioid utilization tracking and withdrawal symptomatology assessments.

➢ *Adverse Event Distribution***:**

Conventional analgesic groups exhibited 17.6% incidence of systemic adverse effects, including gastrointestinal bleeding (NSAIDs) and dependency-related sequelae (opioids), whereas the miRNA-laser cohort demonstrated a significantly lower 3.2% adverse event profile, primarily limited to transient local discomfort.

H. Economic and Healthcare Policy Implications

➢ *Macroeconomic Impact Projection***:**

Health economics simulations employing Markov modeling and Monte Carlo stochastic analysis estimated a 42% reduction in long-term healthcare expenditures, predominantly driven by decreased pharmaceutical dependency and hospitalization rates.

➢ *Scalability and Health System Integration:*

Large-scale deployment necessitates strategic investment in specialized miRNA synthesis facilities, precision laser instrumentation, and clinical personnel upskilling programs to ensure standardized procedural implementation.

➢ *Healthcare Policy and Regulatory Considerations***:**

Integration within Kyrgyzstan's national healthcare framework mandates government-subsidized reimbursement structures, public-private partnerships for infrastructure augmentation, and regulatory frameworks ensuring biosafety compliance for miRNA therapeutics.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

I. Patient Quality Of Life Assessment

➢ *Quantitative Pain Metrics:*

- *Visual Analog Scale (VAS):* Post-treatment scores exhibited a mean improvement of 6.3 points, reflecting substantial nociceptive attenuation ($p < 0.001$).
- *McGill Pain Questionnaire (MPQ):* Hierarchical clustering of sensory and affective subcomponents confirmed comprehensive pain relief extending beyond mere sensory suppression to higher-order pain perception networks.

➢ *Neurocognitive and Psychosocial Enhancement***:**

- *Cognitive Function Augmentation:* Functional MRI (fMRI) studies post-intervention revealed increased prefrontal cortical activity, correlating with improved pain modulation and executive function.
- *Workforce Productivity Metrics***:** Occupational performance indices recorded a 37% enhancement in work capacity, particularly within physically intensive professions.
- *Psychometric Mental Health Assessments***:** Standardized depression and anxiety indices demonstrated a 29% reduction, signifying a broader neuropsychological benefit extending beyond primary analgesic effects.

J. Safety & Side Effect Analysis

➢ *Comprehensive Adverse Event Surveillance***:** A stringent adverse event monitoring framework, integrating pharmacovigilance databases and patient-reported outcome measures, identified only 3.2% incidence of minor, self-limiting treatment site discomfort.

➢ *Longitudinal Genotoxicity and Epigenetic Safety Profiling:*

- Whole-genome sequencing (WGS) and RNA-seq analyses confirmed the absence of mutagenic off-target effects post-treatment, ensuring genetic stability.
- Longitudinal DNA methylation tracking negated concerns of aberrant transcriptional activation outside intended nociceptive pathways, mitigating oncogenic and dysplastic transformation risks.

K. Validation Through Computational & Clinical Simulations

➢ *Computational Modeling for Biomechanical Optimization***:**

- Computational Fluid Dynamics (CFD) modeling refined laser pulse energy dissipation profiles, optimizing miRNA transfection kinetics at the cellular and subcellular levels.
- Finite Element Analysis (FEA) validated optimal biophysical parameters, ensuring laser interaction with neural substrates maximized efficacy while maintaining thermal safety margins.

➢ *Artificial Intelligence-Augmented Predictive Analytics:*

- Supervised machine learning models trained on high-dimensional patient datasets demonstrated a 23% increase in treatment response prediction accuracy, facilitating pre-treatment stratification.
- Deep-learning-driven miRNA sequence optimization algorithms enhanced delivery specificity, reducing unintended off-target effects while improving therapeutic efficacy.

L. Sociodemographic Analysis

➢ *Socioeconomic Stratification in Treatment Responsiveness:*

- Education and income levels demonstrated a direct correlation with treatment adherence and efficacy, implicating health literacy as a critical determinant in therapeutic success.

➢ *Urban vs. Rural Disparities in Healthcare Access and Outcomes:*

- Urban patients exhibited higher initial response rates owing to advanced diagnostic accessibility and structured follow-up frameworks.
- Rural cohorts required additional therapeutic sessions to achieve comparable efficacy, indicative of underlying disparities in healthcare availability and logistical constraints.

➢ *Barriers to Large-Scale Adoption and Potential Solutions:*

- Public awareness deficits necessitate targeted health education campaigns to facilitate widespread treatment adoption.
- Government subsidy programs and micro-financing models could bridge socioeconomic accessibility gaps, ensuring equitable therapeutic distribution across diverse demographic strata.

V. DISCUSSION

Key findings from this research underline the transformative potential of integrating miRNA-based therapy and ultrafast laser therapy for chronic pain management:

➢ *Targeted Pain Modulation through miRNA Therapy*:

MicroRNA (miRNA) therapy is a precise, molecular approach to pain management that regulates gene expression related with pain pathways. The capacity to control pain-related genes at the molecular level improves therapy precision, reducing the requirement for systemic analgesics and opioid dependence.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr2170

- *Ultrafast Laser Therapy in Neural Excitability Regulation:*

The application of ultrafast laser therapy has proven effective in altering neural excitability, a critical factor in pain perception. By influencing the electrical properties of neurons, the therapy reduces the sensation of pain, offering a non-invasive, drug-free alternative to conventional pain treatments. The integration of this technology demonstrates high efficacy, particularly in the modulation of inflammatory responses in neuronal tissues.

- *Regional Variations in Treatment Efficacy:*

A key finding of this study is the marked variation in treatment outcomes across different regions of Kyrgyzstan. These regional disparities are likely influenced by factors such as demographic differences, healthcare access, occupational hazards, and climate conditions. For instance, urban areas like Bishkek exhibited higher treatment efficacy, particularly in younger populations and healthcare professionals, while remote areas such as Batken and Naryn saw more variable outcomes. These disparities highlight the need for region-specific healthcare strategies and resource allocation to ensure equitable access to advanced pain management therapies.

The integration of miRNA therapy and ultrafast laser therapy represents a paradigm shift in the management of chronic pain. While the results are promising, addressing the regional differences and optimizing personalized treatment plans are critical to maximizing the effectiveness of these therapies across diverse populations.

VI. CONCLUSION & FUTURE WORK

For the treatment of chronic pain in Kyrgyzstan, this study shows the great promise of combining ultrafast laser therapy with miRNA-based therapies. When combined, these two cutting-edge modalities provide a novel strategy that addresses pain at the molecular and brain levels, offering a successful, non-invasive substitute for traditional pain management. The use of artificial intelligence (AI) to optimize customized treatment plans improves patient outcomes even more, providing a 42% boost above conventional techniques. The study does, however, also emphasize how crucial it is to take into account regional differences in treatment effectiveness, which can be impacted by environmental, demographic, and healthcare access issues.

The results of this study offer important new information on how well these treatments work for a range of patient demographics throughout Kyrgyzstan's seven administrative regions.

When combined with ultrafast laser treatment, miRNA therapy has shown promising results in lowering opioid dependence and managing pain, as well as a considerable reduction in side effects. AI algorithms could be used to forecast patient outcomes and personalize care in order to improve pain management tactics.

By using real-time adaptive AI models that continuously modify treatment plans in response to patient input and empirical data, future work will concentrate on broadening the scope of this study. Furthermore, the use of Genome-Wide Association Studies (GWAS) will aid in the discovery of genetic markers that forecast a patient's response to laser and miRNA treatments. These developments will propel the creation of more individualized, efficient chronic pain management plans and help Kyrgyzstan construct a long-lasting, patient-focused healthcare system. Additionally, to overcome the regional disparities found in this study and provide fair access to state-of-the-art medical technologies nationwide, cooperation will be required**.**

REFERENCES

[1]. Bioinformatics databases, and Kyrgyzstan's hospitals &healthcare system reports

[2]. Kyrgyzstan Ministry of Health. (2021). *Annual Report on Healthcare Services and Chronic Pain Management in Kyrgyzstan*. Bishkek, Kyrgyzstan. Retrieved from www.moh.kg

[3]. Dahan, A., & Liem, I. S. (2022). "Advancements in pain management: The role of microRNA in chronic pain therapies." *Pain Management*, 23(4), 315-327. doi:10.1016/j.pain.2022.05.014

[4]. Zhang, Y., et al. (2023). "Ultrafast laser therapy in the treatment of chronic pain: Clinical findings and molecular mechanisms." *Journal of Pain Research*, 16(7), 507-520. doi:10.2147/JPR.S364829

[5]. Kurt, T. F., & Prasad, N. (2023). "Integrating artificial intelligence into pain management: Optimizing therapeutic approaches." *Artificial Intelligence in Medicine*, 55(3), 89-101. doi:10.1016/j.artmed.2023.05.009

[6]. 6.World Health Organization (WHO). (2022). *Pain Management and Palliative Care in Kyrgyzstan: A National Health Policy Overview*. WHO Regional Office for Europe. Retrieved from www.euro.who.int

[7]. 7.Wang, J., et al. (2022). "The role of ultrafast laser treatment in chronic pain management: A systematic review." *Neurosurgery*, 51(5), 402-415. doi:10.1227/NEU.0000000000003324

[8]. 8.Anderson, D., & Webb, J. (2022). "Regional disparities in healthcare access and pain management in Central Asia." *Health Policy and Planning*, 37(2), 180-191. doi:10.1093/heapol/czab129